Thanks for your considered post Twotic!
Makes a pleasant change from the boring, repetitive, and inflammatory rhetoric coming from certain unbalanced posters.
I agree with much of what you said, having watched the live stream rather than attended in person, but since I was greatly reassured by what Jackie Walker said (including the info about the "thinly spread" marketing coverage), I am still in. (Note however that I am a very small shareholder and don't stand to lose a lot of money - I certainly still view PEB as a fairly risky investment.)
Quote:
Perhaps enough has been said about Chris Swan but he was so bad I feel I have to make comment. During the meeting I sat there and watched him twitch and shuffle his way through his opening address. His body position literally changed every 3 or 4 seconds, tapping away with each foot in turn. I wanted to give him the benefit of the doubt that perhaps he is just a very nervous guy, but as the meeting went on it was clear he was incredibly under-prepared and that his knowledge of many areas of the business was severely lacking.
Perhaps, as others suggested, he viewed the meeting as a necessary inconvenience and hadn't bothered spending the time to fully prepare or rehearse for it? I do not view Chris Swann as being key to the success of PEB, so even though his public performance as Chair was disappointing, I don't believe he will have any material affect on whether or not PEB will be successful.
Quote:
On the face of it Dave Darling actually speaks quite well, but unless he is talking about the product itself or the genuine concern for the well being of cancer sufferers, my take is he is ofetn full of hot air. This was typified in his response to happenings over in OZ and Spain which was a complete joke.
He needs to lay off the repeated use of "exciting" and "great outcome" etc. He is a confident and knowledgeable speaker, but repeating the same positive phrases just starts to sound hollow. He needs to let the results speak for themselves.
Quote:
CMS and VA cover still appear to be so far away no commitment can be given on any time lines.
I got the impression that they were not far away from VA approval, having now submitted their "dossier" (maybe early 2016?), and that CMS coverage would likely come sometime in 2016 also.
Quote:
The other thing I just don’t get is given how thinly spread they are in the US what on earth are they doing exploring Asia?
Jackie mentioned how they had engaged an independent marketing company to help them identify key coverage areas ("heat map" and 60% of urologists in the 19 urban centres etc.) and since I have no knowledge/experience of marketing diagnostic tests in the US, I can only assume that Jackie Walker and the marketing company know what they are doing.
Quote:
I do believe they have a good product but there is certainly not enough of an evidence base for it to become part of the best practice clinical pathway in the short (perhaps even medium) term. I have been told this directly by people with first hand experience with the product, and the AHRQ report effectively reiterated this as well. Moreover, I am genuinely concerned their product may simply be not good enough anyway.
Are the people you have spoken to with first hand experience in NZ or in the US? There are very big difference between the US and NZ in terms of the pathways involved for uptake as best practice...
Ultimately every investor has to do what they feel most comfortable with. For now I am still comfortable with being a shareholder in PEB, but I can understand why others might not be. :cool: